Interviews

Nathan Bahary, MD, discussed with Targeted Oncology how the cholangiocarcinoma treatment paradigm has changed and what is on the horizon for treatment and care of patients.

Ronald S. Go, MD, explains how toxicities of treatment for histiocytic neoplasms compared with toxicities observed in other malignancies.

Joshua K. Sabari, MD, discusses the trials that showed efficacy for durvalumab and atezolizumab in patients with extensive-stage small cell lung cancer.

Bhavana Pothuri, MD, discusses the results of the KEYNOTE-775 trial in patients with advanced endometrial cancer in relation to microsatellite instability status.

Julie Renee Brahmer, MD, MSc, discusses upcoming and recent trials that may change the sequencing of targeted therapies in patients with locally advanced non–small cell lung cancer.

Bradley J. Monk, MD, FACOG, FACS, discusses the use of immune checkpoint inhibitors to treat cervical cancer.

Patrick Connor Johnson, MD, discusses what physicians take into consideration when integrating third-line treatment options in diffuse large B-cell lymphoma

Jeffrey Zonder, MD, discusses the efficacy results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.

According to Bradley J. Monk, MD, FACOG, FACS, cemiplimab achieved better response and a longer overall survival compared with chemotherapy in patients with cervical cancer.

Lee Schwartzberg, MD, discusses the results of the KEYNOTE-522 trial of pembrolizumab in patients with early triple-negative breast cancer.

Dennis Scribner, Jr, MD, discusses the challenges for reaching patients who are at the greatest risk of developing cervical cancer.

Jeffrey Zonder, MD, discusses the safety results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.

During the 2022 Gastrointestinal Cancers Symposium, Zev A. Wainberg, MD, predicts how gastric cancer treatment will look in the near future.

Megan May, PharmD, discusses fitting newer targeted therapies into the treatment paradigm for EGFR exon 20 insertion mutation-positive non–small cell lung cancer.

Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.

Mark A. Socinski, MD, discusses the safety profile of tepotinib that was observed in the VISION trial of patients with advanced or metastatic non–small cell lung cancer with MET exon 14 skipping mutations.

Ghassan K. Abou-Alfa, MD, discusses the use of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma, as investigated in a phase 2 clinical trial.

National Cancer Institute expert, Christopher J. Melani, MD, discusses the synergy of 5 drugs that make up a targeted therapy regimen for patients with mantle cell lymphoma.

Alice S. Mims, MD, MSCR, discusses new regimens for treating patients with acute myeloid leukemia, including anti-CD47 immunotherapy, IDH inhibitors, and menin inhibitors.

Leora Horn, MD, discusses the importance of the Impower133 trial.

Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Jennifer R. Brown, MD, PhD, discusses the interim results of the SEQUOIA trial , which investigated the combination of zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.

Krzysztof J. Misiukiewicz, MD, discusses sequencing of treatments in patients with NTRK-positive thyroid cancer.

Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.

Daniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.

Rebecca C. Arend, MD, discusses the key unmet needs in the treatment landscape for platinum-resistant ovarian cancer.

Cristiane D. Bergerot, PhD, discusses how financial toxicity associated with renal cell carcinoma is impacting oncologists and their patients.

William J. Gradishar, MD, discusses the design and results of a study of intravenous versus subcutaneous pertuzumab and trastuzumab in patients with HER2-positive breast cancer.

Clayton Lau, MD, advises primary care physicians and specialists on how to help address the rising prevalence of advanced-stage genitourinary cancers.